Once hailed by former Gilead Sciences Inc. CEO and President John Milligan as "the beginning of a very important NASH franchise," the oral apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib has again failed to meet the primary endpoint in a phase III trial. Top-line results of the Stellar-3 study for patients with bridging fibrosis due to nonalcoholic steatohepatitis (NASH) did not meet the prespecified week 48 primary endpoint of a ≥ 1-stage histologic improvement in fibrosis without worsening of the condition after failing to meet a similar endpoint for NASH patients with compensated cirrhosis in Stellar-4.